Organogenesis Holdings earnings release, May 7, 2026

Organogenesis Holdings Inc. (ORGO) · Form 8-K, Item 2.02 · Filed · SEC filing

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

CANTON, Mass.,

(May 7, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Results Summary:

• Net revenue of $36.3 million for the first quarter of 2026, a decrease of $50.4 million compared to net revenue of $86.7 million for the first quarter of 2025. Net revenue for the first quarter of 2026 consists of: o

Net revenue from Advanced Wound Care products of $29.5 million, a decrease of 63% from the first quarter of 2025. o

Net revenue from Surgical & Sports Medicine products of $6.8 million, consistent with the first quarter of 2025.

• Net loss of $53.2 million for the first quarter of 2026, compared to a net loss of $18.8 million for the first quarter of 2025, an increase in net loss of $34.3 million.

• Adjusted net loss of $43.7 million for the first quarter of 2026, compared to an adjusted net loss of $13.4 million for the first quarter of 2025, an increase in adjusted net loss of $30.3 million.

• Adjusted EBITDA loss of $48.2 million for the first quarter of 2026, compared to Adjusted EBITDA loss of $12.5 million for the first quarter of 2025, an increase in EBITDA loss of $35.6 million.

“The first quarter presented a challenging start to the year, as expected; however, we remain well positioned to navigate this period of unprecedented disruption and continue to expect to drive significant market share gains in the second half of 2026,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board for Organogenesis. “We remain confident in the long-term opportunity for Organogenesis, supported by the largest, most comprehensive portfolio across multiple FDA classifications, a significant achievement with the ReNu BLA submission, and an ever-expanding body of clinical evidence.”

First Quarter 2026 Financial Results:

Net product revenue for the first quarter of 2026 was $36.3 million, compared to $86.7 million for the first quarter of 2025, a decrease of $50.4 million, or 58%. The decrease in net product revenue was driven by a decrease of $50.4 million, or 63%, in net product revenue for Advanced Wound Care products.

Gross profit for the first quarter of 2026 was $10.5 million, or 29% of net product revenue, compared to $63.0 million, or 73% of net product revenue for the first quarter of 2025, a decrease of $52.5 million, or 83%.

Operating expenses for the first quarter of 2026 were $106.1 million compared to $113.4 million for the first quarter of 2025, a decrease of $7.3 million, or 6%. Cost of goods sold was $25.8 million for the first quarter of 2026, compared to $23.7 million for the first quarter of 2025, an increase of $2.0 million, or 9%.

Selling, general and administrative expenses were $65.2 million for the first quarter of 2026, compared to $72.5 million for the first quarter of 2025, a decrease of $7.3 million, or 10%. R&D expense was $15.2 million for the first quarter of 2026, compared to $10.6 million for the first quarter of 2025, an increase of $4.5 million, or 42%. For the three months ended March 31, 2025, the Company recorded write-down expenses of $6.6 million.

Operating loss for the first quarter of 2026 was $68.9 million, compared to an operating loss of $26.7 million for the first quarter of 2025, an increase in operating loss of $42.1 million.

Total other income, net, for the first quarter of 2026 was $0.4 million, compared to $1.0 million for the first quarter of 2025, a decrease of $0.5 million.

Net loss for the first quarter of 2026 was $53.2 million, or $(0.44) per share, compared to net loss of $18.8 million, or $(0.17) per share, for the first quarter of 2025, an increase in net loss of $34.3 million, or $(0.27) per share.

Adjusted net loss was $43.7 million for the first quarter of 2026, compared to adjusted net loss of $13.4 million for the first quarter of 2025, an increase in adjusted net loss of $30.3 million.

Adjusted EBITDA loss was $48.2 million for the first quarter of 2026, compared to Adjusted EBITDA loss of $12.5 million for the first quarter of 2025, an increase in adjusted EBITDA loss of $35.6 million.

Non-GAAP operating loss was $56.0 million for the first quarter of 2026, compared to non-GAAP operating loss of $19.3 million for the first quarter of 2025, an increase in non-GAAP operating loss of $36.7 million.

As of March 31, 2026, the Company had $92.1 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2025.

Fiscal Year 2026 Outlook:

For the year ending December 31, 2026, the Company now expects:

• Total net revenue between $270.0 million and $310.0 million, representing a decline in the range of 45% to 52%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025. o

The 2026 total net revenue guidance range assumes a sequential improvement in revenue trends in the second quarter, however, at a more measured rate versus what the prior guidance assumed resulting in a first half revenue decline in the range of approximately 52% to 49% year over year. We continue to expect strong sequential revenue growth in the third and fourth quarters of 2026, however, the low-end of the guidance range now assumes a more prolonged recovery in market-related headwinds resulting in a second half revenue decline similar to the first half of 2026.... (truncated)Call:

Management will host a conference call at 5:00 p.m. Eastern Time on May 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

ORGANOGENESIS HOLDINGS INC.

UNAUDITED CONDENSED CONSOLIDATED BA

LANCE SHEETS

(amounts in thousands, except share and per share data)

Financial statements

Income Statement

Three Months Ended March 31, — (amounts in thousands, except share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Net product revenue36,25086,693
Revenue:Grant income978
Revenue:Total revenue37,22886,693
Operating expenses:Cost of goods sold25,77223,723
Operating expenses:Selling, general and administrative65,18672,509
Operating expenses:Research and development15,16110,640
Operating expenses:Write-down to fair value for asset held for sale6,567
Operating expenses:Total operating expenses106,119113,439
Operating expenses:Loss from operations-68,891-26,746
Other income, net:Interest income, net380961
Other income, net:Other income, net382
Other income, net:Total other income, net418963
Other income, net:Net loss before income taxes-68,473-25,783
Other income, net:Income tax benefit15,3176,940
Other income, net:Net loss and comprehensive loss-53,156-18,843
Other income, net:Accretion of redeemable convertible preferred stock to redemption value-159-121
Other income, net:Cumulative dividend on redeemable convertible preferred stock-2,844-2,627
Other income, net:Net loss attributable to common stockholders-56,159-21,591
Net loss, per share:Basic and diluted-0.44-0.17
Weighted-average common shares outstandingBasic and diluted127,797,013126,295,642

Income Statement

Three Months Ended March 31, — The following table presents a reconciliation of GAAP net loss to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented: (in thousands)

Three Months Ended March 31, – 2026 – (Unaudited, in thousands)Three Months Ended March 31, – 2025 – (Unaudited, in thousands)
Net loss-53,156-18,843
Interest income, net-380-961
Income tax benefit-15,317-6,940
Depreciation and amortization4,1743,444
Amortization of intangible assets (1)5,708842
EBITDA-58,971-22,458
Stock-based compensation expense3,6363,367
Inventory write-downs (2)3,327
Restructuring charge (3)3,858
Write-down to fair value for asset held for sale (4)6,567
Adjusted EBITDA-48,150-12,524

Income Statement

Three Months Ended March 31, — The following table presents a reconciliation of GAAP net loss from operations to non-GAAP operating loss, for the periods presented: (in thousands)

Three Months Ended March 31, – 2026 – (Unaudited, in thousands)Three Months Ended March 31, – 2025 – (Unaudited, in thousands)
Loss from operations-68,891-26,746
Amortization of intangible assets (1)5,708842
Inventory write-downs (2)3,327
Restructuring charge (3)3,858
Write-down to fair value for asset held for sale (4)6,567
Non-GAAP operating loss-55,998-19,337

Balance Sheet

December 31, — (amounts in thousands, except share and per share data)

March 31, – 2026December 31, – 2025
Current assets:Cash and cash equivalents91,37993,679
Current assets:Restricted cash720652
Current assets:Accounts receivable, net116,908217,451
Current assets:Inventories, net28,42529,627
Current assets:Asset held for sale2,4252,425
Current assets:Prepaid expenses and other current assets28,64418,354
Current assets:Total current assets268,501362,188
Current assets:Property and equipment, net104,078103,711
Current assets:Intangible assets, net3,4379,145
Current assets:Goodwill28,77228,772
Current assets:Operating lease right-of-use assets, net53,74255,749
Current assets:Deferred tax asset, net45,33329,962
Current assets:Other assets16,1299,203
Current assets:Total assets519,992598,730
Current liabilities:Current portion of finance lease obligations5089,435
Current liabilities:Current portion of operating lease obligations - related party4,4514,258
Current liabilities:Current portion of operating lease obligations4,7644,949
Current liabilities:Accounts payable28,61531,949
Current liabilities:Accrued expenses and other current liabilities37,68349,533
Current liabilities:Total current liabilities76,021100,124
Current liabilities:Finance lease obligations, net of current portion12,35812,788
Current liabilities:Operating lease obligations, net of current portion - related party26,99328,237
Current liabilities:Operating lease obligations, net of current portion21,78722,470
Current liabilities:Other liabilities1,4861,193
Current liabilities:Total liabilities138,645164,812
Commitments and contingencies (Note 15)Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding at March 31, 2026 and December 31, 2025; liquidation preference of $145,061 and $142,217 at March 31, 2026 and December 31, 2025, respectively.136,792133,789
Stockholders’ equity:Common stock, $0.0001 par value; 400,000,000 shares authorized; 129,403,096 and 127,680,424 shares issued; 128,674,548 and 126,951,876 shares outstanding at March 31, 2026 and December 31, 2025, respectively.1313
Stockholders’ equity:Additional paid-in capital300,776303,194
Stockholders’ equity:Accumulated deficit-56,234-3,078
Stockholders’ equity:Total stockholders’ equity244,555300,129
Stockholders’ equity:Total liabilities, redeemable convertible preferred stock, and stockholders' equity519,992598,730

Cash Flow

Three Months Ended March 31, — (amounts in thousands, except share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Cash flows from operating activities:Net loss-53,156-18,843

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Organogenesis Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.